This project aims to advance our knowledge of aortic stenosis (AS), a common and life-threatening heart valve condition affecting 1 in 8 elderly Australians, and will consist of 3 interconnected components:
1. Analysis of Australian registry data to establish the current landscape of treatment and outcomes for AS patients undergoing transcatheter aortic valve implantation (TAVI).
2. A study assessing the haemodynamic profiles of AS patients pre and post-TAVI using cardiac catheterisation techniques, with a specific focus on defining the relationship between AS and another heart condition, heart failure with preserved ejection fraction (HFpEF).
3. A clinical trial evaluating whether dapagliflozin, a drug shown to improve outcomes in HFpEF, also benefits patients with AS after TAVI. Our findings will contribute to an enhanced understanding of the mechanisms underlying AS and potentially pave the way for the development of new treatments.
Our findings will contribute to an enhanced understanding of the mechanisms underlying AS and potentially pave the way for the development of new treatment
Last updated12 March 2024